.Attributes Medication, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medication conjugate (ADC) tisotumab vedotin resulted in enhanced progression-free and general survival, resulting in FDA commendation and a brand new procedure choice for people.